Targeting the 19S proteasomal subunit, Rpt4, for the treatment of colon cancer. by Boland, Karen et al.
Royal College of Surgeons in Ireland
e-publications@RCSI
Physiology and Medical Physics Articles Department of Physiology and Medical Physics
17-3-2016
Targeting the 19S proteasomal subunit, Rpt4, for
the treatment of colon cancer.
Karen Boland
Royal College of Surgeons in Ireland
Lorna Flanagan
Royal College of Surgeons in Ireland
Niamh McCawley
Royal College of Surgeons in Ireland
Ritesh Pabari
Royal College of Surgeons in Ireland, riteshpabari@rcsi.ie
Elaine Kay
Royal College of Surgeons in Ireland
See next page for additional authors
This Article is brought to you for free and open access by the Department
of Physiology and Medical Physics at e-publications@RCSI. It has been
accepted for inclusion in Physiology and Medical Physics Articles by an
authorized administrator of e-publications@RCSI. For more information,
please contact epubs@rcsi.ie.
Citation
Boland K, Flanagan L, McCawley N, Pabari R, Kay EW, McNamara DA, Murray F, Byrne AT, Ramtoola Z, Concannon CG, Prehn
JHM. Targeting the 19S proteasomal subunit, Rpt4, for the treatment of colon cancer. European Journal of Pharmacology. 2016;
780:53-64.
Authors
Karen Boland, Lorna Flanagan, Niamh McCawley, Ritesh Pabari, Elaine Kay, Deborah McNamara, Frank
Murray, Annette Byrne, Zebunnissa Ramtoola, Caoimhín Concannon, and Jochen Prehn
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/physiolart/94
— Use Licence —
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/physiolart/94
1 
 
Targeting the 19S proteasomal subunit, Rpt4, for the treatment of colon cancer 
Karen Boland1, 2, Lorna Flanagan1, Niamh McCawley1,3, Ritesh Pabari5, Elaine W. Kay4, 
Deborah A. McNamara3, Frank Murray2, Annette T. Byrne1, Zebunnissa Ramtoola5*, 
Caoimhín G. Concannon1*, and Jochen H.M. Prehn1 
 
1Centre for Systems Medicine and Department of Physiology and Medical Physics, Royal 
College of Surgeons in Ireland, 123 St Stephen’s Green, Dublin 2, Ireland;  Departments of 
2Gastroenterology, 3Surgery, and 4Pathology, Beaumont Hospital, Beaumont, Dublin 9, 
Ireland; 5School of Pharmacy, Royal College of Surgeons in Ireland, York House, York 
Street, Dublin 2, Ireland 
 
* Both authors contributed equally to this work.  
To whom correspondence should be addressed: 
Prof. Jochen H.M. Prehn 
Department of Physiology and Medical Physics 
Royal College of Surgeons in Ireland 
123 St. Stephen’s Green 
Dublin 2, Ireland 
Phone: +353 – 1 – 402 – 2255  
FAX: + 353 – 1 – 402 – 2447 
E-mail: jprehn@rcsi.ie 
 
The authors disclose no potential conflicts of interest. 
 
This research was supported by grants from the Health Research Board, Ireland 
(APOCOLON; TRA/2007/26; HRA_POR/2012/121) to JHMP, EWK and FM, and Science 
Foundation Ireland (13/IA/1881) to JHMP.  
Word Count: 5,463 
2 
 
Abstract 
Deregulation of the ubiquitin-proteasome pathway has been frequently observed in a number 
of malignancies. Using quantitative Western blotting of normal and matched tumour tissue, 
we here identified a significant increase in the 19S proteasome subunit Rpt4 in response to 
chemoradiation in locally advanced rectal cancer patients with unfavourable outcome. We 
therefore explored the potential of Rpt4 reduction as a therapeutic strategy in colorectal 
cancer (CRC). Utilizing siRNA to down regulate Rpt4 expression, we show that silencing of 
Rpt4 reduced proteasomal activity and induced endoplasmic reticulum stress. Gene silencing 
of Rpt4 also inhibited cell proliferation, reduced clonogenic survival and induced apoptosis in 
HCT-116 colon cancer cells.  We next developed a cell penetrating peptide-based 
nanoparticle delivery system to achieve in vivo gene silencing of Rpt4. Administration of 
Rpt4 siRNA nanoparticles reduced tumour growth and improved survival in a HCT-116 
colon cancer xenograft tumour model in vivo. Collectively, our data suggest that inhibition of 
Rpt4 represents a novel strategy for the treatment of CRC. 
 
Key words: proteasome, colorectal cancer, Rpt4, nanocomplexes, chemotherapy  
 
   
3 
 
1.0  Introduction 
 
Colorectal cancer (CRC) is the third leading cause of cancer-related mortality in the United 
States according to data collected by the Centre for Disease Control (CDC) and the American 
Cancer Society, with an average lifetime risk of 5.1% (Jemal et al., 2010). Developments in 
adjuvant chemotherapy and radiotherapy have a role in increasing overall survival, although 
surgical resection remains the mainstay of curative treatment where clinically appropriate.  
However, resistance to (radio)chemotherapy is one of the leading causes of treatment failure 
in CRC (Violette et al., 2002). As such, novel therapeutic strategies are required to increase 
overall patient survival as well as providing alternative treatment paradigms to patients who 
become chemo-resistant to standard therapies. 
 
Regulated degradation of proteins is central to the maintenance of cellular homeostasis. The 
majority of intracellular protein degradation is mediated via the ubiquitin-proteasome 
pathway (Ciechanover et al., 1991).  The mammalian 26S proteasome is composed of a 20S 
core particle which houses the sites of active proteolysis within its inner β-subunit rings, and 
two 19S outer regulatory particles which are attached to the α-ring (Glickman and 
Ciechanover, 2002). This is a complex structure which influences many cellular processes 
including cell cycle, apoptosis, stress responses and cellular differentiation (Adams, 2004; 
Nakayama and Nakayama, 2006). Substrates of the ubiquitin-proteasome degradation 
pathway known to be regulators of these processes include the tumour suppressor p53, 
cyclins, B, Inhibitor of Apoptosis Proteins (IAPs), and Bcl-2 family of proteins 
(Jesenberger and Jentsch, 2002)  (Zinszner et al., 1998).  The 19S regulatory particles consist 
of a lid and base which act together to confer further substrate specificity to the process of 
proteasomal degradation.  This 19S base has a ring of six AAA ATPases, Rpt1-6 (Regulatory 
Particle ATPases 1-6) (Braun et al., 1999).  They enable ATP-dependent function of the 19S 
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regulatory particle with their role in the recognition of polyubiquitylated substrates for 
protein degradation, and substrate unfolding for translocation into the 20S core using reverse 
chaperoning (Adams, 2004; Braun et al., 1999). Therefore, the 19S subunits are essential for 
the degradation of these polyubiquitylated proteins which collectively form the largest group 
of proteasomal substrates. 
 
Deregulation of the ubiquitin-proteasome pathway has been identified in a variety of 
malignancies (Bazzaro et al., 2006; Chen and Madura, 2005; Mani and Gelmann, 2005). The 
differential sensitivity of malignant cells to proteasome inhibition (Eldridge and O'Brien, 
2009), leading to induction of cell death and apoptosis and enhanced sensitivity to 
chemotherapy have validated the use of  proteasome inhibitors such as bortezomib for the 
treatment of multiple myeloma (Richardson et al., 2003) and mantle cell lymphoma (Fisher et 
al., 2006).  Bortezomib is a reversible inhibitor of the 26S proteasome, and acts 
synergistically to enhance the effects of conventional chemotherapeutic agents and may 
overcome acquired resistance (Milano et al., 2007; Orlowski and Baldwin Jr, 2002).  
However, the use of bortezomib has been associated with dose related induction of 
neuropathies (Bruna et al., 2010; Cavaletti et al., 2007). Given the existence of potential 
resistance mechanisms and the unwanted side effects of broad proteasome inhibition, there is 
a need for more targeted approaches to proteasome inhibition.  Increased activity of the 
proteasome has been noted in colon cancer (Arlt et al., 2009; Chen et al., 2009) and we have 
previously demonstrated that Rpt4 (PSMC6) is differentially expressed in colorectal cancer 
tissue when a panel of proteasomal subunits including 20S core, Rpt4 and polyubiquitylated 
proteins were tested.  Analysis of Rpt4 protein levels using immunohistochemistry in Stage 2 
node-negative patients with colon cancer showed that increased Rpt4 staining was associated 
with disease free survival as well as overall survival.  This indicates that in Stage 2 colorectal 
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cancer that Rpt4 is a prognostic biomarker for these patients, and potentially select the patient 
cohort who may benefit from adjuvant chemotherapy (McCawley et al., 2012).  Therefore, 
we tested the hypothesis that specific inhibition of the proteasome subunit Rpt4 (PMSC6) 
represents a novel strategy for the treatment of CRC.   
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2.0  Materials and Methods 
 
2.1  Patient samples  
All tissue was sourced from an institutional review board approved tissue bio-bank 
maintained at Beaumont Hospital, Ireland. Informed consent was obtained from each 
participating patient.  A cohort of patients with colon cancer was selected from the Bowel 
Cancer database for which clinical follow up was available. Colonic resection specimens 
were sent fresh to the Pathology Department where a trained technician obtained tumour and 
adjacent normal tissue specimens, which were then snap frozen. Standard pathology reports 
for the resected colon tumours were issued. Biopsy tissue, both tumour and matched normal, 
was obtained from a separate cohort of rectal cancer patients at colonoscopy or rigid 
sigmoidoscopy, prior to neoadjuvant radio chemotherapy. Following treatment, surgical 
resection tissue was obtained for these patients. Histology was verified by an experienced 
pathologist, and tissues were evaluated to ensure consistent quality and tumour presence. 
Clinical follow-up and response to neoadjuvant radio chemotherapy was reported by a 
dedicated clinical research nurse.  Specific ethical approval for this research was obtained 
from the Beaumont Hospital Research Ethics Committee in compliance with local protocols. 
 
2.2  Western blotting  
Patient samples were lysed in 400 ml ice-cold buffer -50 mmol/l HEPES (pH 7.5), 150 
mmol/l NaCl, 5 mmol/l Na-EDTA and protease inhibitor (Sigma).  Samples were kept on ice 
and homogenized using 30 s pulses with the Ultra-Turrax T25 Basic Homogeniser. Cell line-
derived samples were lysed in SDS-lysis buffer [62.5 mM Tris/HCl (pH 6.8), Glycerin 10%, 
SDS 2%, H2O]. Protein concentrations were determined using the standard Pierce Micro-
BCA Protein Assay (Pierce, Northumberland, UK).  Western blotting was performed using 
mouse monoclonal antibodies to Rpt4 (Enzo Life Sciences, Exeter, UK), Grp78/KDEL 
7 
 
(StressGen, Ann Arbor, MI, USA), pUbq (Biomol, Enzo Life Sciences, Exeter, UK), α-
tubulin or -actin (Sigma, Dublin, Ireland).  Secondary antibodies coupled to horse radish 
peroxidase were detected using a Fujifilm LAS 4000 imager (Fuji, Sheffield, UK). 
 
2.3  Cell culture and treatment 
HCT-116 wt and p53 -/- cells were obtained from Prof. Bert Vogelstein (Johns Hopkins 
University, Baltimore, MD). The authenticity of the cell lines was confirmed by DNA STR 
profiling conducted by the DSMZ in October 2012 and all experiments were carried out 
within six months of authentication. Cells were grown in RPMI 1640 medium supplemented 
with 10% FCS, 2 mM L-Glutamine, 100 U/ml penicillin and 100 g/ml streptomycin. HT-29, 
LoVo and CRL 1807 cells were grown in DMEM containing 100 U/ml penicillin and 100 
g/ml streptomycin. Cells were cultured at 37°C in 5% CO2 and maintained in logarithmic 
growth by sub-culturing twice weekly. In indicated experiments cells were treated with a 
combination of 5-fluoururacil (30 μg/ml) and oxaliplatin (10μg/ml) diluted in fresh medium 
or vehicle as control.   
 
2.4  Transfection with siRNA 
HCT116 cells were seeded at a density of 6 x 105 cells per well in a 24 well plate for 24 h 
prior to transfection using Metafectene (Biontex, Martinsried Germany) with siRNA 
duplexes (Sigma-Aldrich) with either a control sequence or Rpt4 targeting sequence at a final 
concentration of 50 nM of siRNA in 1 ml of OptiMEM. The sequences used were: 
UUCUCCGAACGUGUCACGUdTdT for control;  GGAGUUAAGGGAACAAUUAdTdT 
for Rpt4 sequence 1;  UAACUGUUUAAGCACUUCAdTdT for Rpt4 sequence 2.  
 
2.5  Quantitative Polymerase Chain Reaction (qPCR) analysis 
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Cells were transfected with control siRNA or siRNA targeting Rpt4 (Sigma) when cells were 
70% confluent for RNA extraction.  RNA extraction was completed on ice using a Qiagen 
RNeasy Kit, following described protocol.  Following RNA extraction, the RNA was frozen 
at -80̊ C until used.  RNA was removed from the -80̊ C freezer and thawed once.  RNA 
concentrations were measured using a Nanodrop, calculating concentration in ng/μl and 
generating stocks for a final concentration of 1 μg/μl with sterile RNA free H20.  Sample 
volume was generated to eventually evaluate 10 samples per condition including two 
controls, one without Reverse Transcriptase.  cDNA was then generated using Invitrogen 
reagents.  4 μl dN6 was added to 20 μl RNA/H20 and cycled in thermal cycler for 5 min at 65̊ 
C.  Temperature was then dropped to 4̊ C and again elevated to 25 ̊ C, and immediately the 
process was paused.   Mastermix, generated using reagents from Invitrogen, (8 μl 5x buffer, 4 
μl 0.1M DTT, 2 μl 10mM dTNP3, 1 μl RNAseOUT and 1 μl SS11) was then added to the 
samples to make a total volume of 40 μl, with the exception of the Reverse Transcriptase-free 
control.  The cycle was then resumed on the thermal cycler and when complete, frozen 
overnight at -20̊ C.  qPCR analysis was performed using Lightcycler 2.0 (Roche Diagnostics).  
Primers tested included Actin, Rpt4 and Grp78.  Samples were prepared using Invitrogen 
reagents.  3 samples per condition (control, Rpt4).  We used two controls with either no 
reverse transcriptase or no template.  2 μl cDNA was added to appropriate light capillaries in 
a cooled box, followed by 2 μl RNAse free H20.  Mastermix was generated (SYBR Green 
[Qiagen], RNAse free H20, 10 μM forward primer and 10 μM reverse primer) and a total 
volume of 18 μl was added to capillaries.  After centrifugation at 3000 rpm for 15 seconds, 
these samples were analysed in the light cycler with 50 cycles and relative mononuclear 
quantification.  The qPCR reactions were run initially at 95̊C for 15 min following cycles of 
94̊C for 20 s, 59̊C for 20 s and 72̊C for 20 s. 
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Expression values were calculated having been normalized to Actin as a control target using 
the Lightcycler software and n-fold expression was then calculated using Microsoft Excel. 
 
Primer sequences: 
               Sense Primer                                     Antisense Primer 
Actin      5’-GCTCCGGAAACTGGACATTA-3’      5’-GTCCCGTTTCGTCCTACAA-3’     
Rpt4         5’-ACACTGGATCCTGCTTTGCT-3’       5’-TCGGAACATACCTGCTTCAG-3’ 
Grp 78    5’-TGCAGCAGGACATCAAGTTC-3       5’-CTGCATGGGTGACCTTCTTT-3′ 
 
2.6  Clonogenic survival assay 
At the appropriate time points post transfection cells were trypsinised, counted and 1000 cells 
were reseeded in a 60 mm tissue culture dish and incubated for 9 days in regular media. At 
day 9, the media was removed and the cell colonies were stained with 1 ml of Clonogenic 
Reagent (0.25% 1, 9-dimethyl-methylene blue in 50% ethanol) at room temperature for 45 
min.  Following incubation with the clonogenic reagent, plates were washed twice with PBS. 
Digital images of the plates were subsequently acquired and the number of colonies 
quantified and expressed relative to the control treated cultures.   
 
2.7  Flow cytometry  
Following treatment cells were then collected with trypsin- EDTA and washed once in PBS 
before resuspension in 100 µl of binding buffer (10 mM Hepes, 140 mM NaCl, 2.5 mM Ca 
Cl2) containing Annexin-V FITC conjugated (5 µl/ml) (BioVision, Mountain View, CA, 
USA) and Propidium Iodide (PI) (1 µg/ml). Cells were stained at room temperature for 20 
min and then analysed immediately on a Partec Cyflow ML16 flow cytometer (Partec, 
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Münster, Germany) equipped with a 488 nm argon ion laser, a 532 nm diode laser and a 405 
nm diode laser. Data was analysed using the Partec FloMax software. 
 
2.8  Proteasome Activity Assay 
Cells were plated at a density of 1 x 105 in a 12 well plate and incubated at 37° C for 24 h and 
then transfected as indicated. Cells were lysed after 72 h by addition of 500 μl of sterile 
filtered lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 5 mM Na-EDTA) to each well 
and plates were agitated for 3 min and then frozen at -80° C. In addition, wells of 
untransfected cells treated with 50 nM bortezomib for 3 h as a positive control were similarly 
lysed. For the activity assay 96 well black clear-bottomed plates were used, testing each 
condition in duplicate.  Substrates were prepared on ice, adding 150 μl sterile filtered reaction 
buffer (25 mM HEPES pH 7.4, 1 mM EDTA, 0.1% CHAPS and 10% Sucrose) per well with 
10 mM of appropriate substrate 3 (Sigma) measuring trypsin-like proteasome activity, 10 
mM substrate 6 (Sigma) measuring chymotrypsin-like proteasome activity or 10 mM 
Caspase-like substrate (Z leu leu Glu-AMC, BML).  50 μl of each condition from 12-well 
plates were added to substrates.  The fluorescence of each sample was measured at 380/460 
nm using a microplate reader (GENios, Tecan) every min for 30 min. The fluorescence/min 
was calculated by linear regression and was corrected for protein content. 
 
2.9  MTT cell viability assay 
Following treatment, thiazolyl blue tetrazolium bromide (MTT, 1 mg/ml; Sigma) was added 
to each well and incubated in the dark at 37°C. After 4 h, the medium was aspirated and the 
dark blue crystals were dissolved in DMSO (200 µl/well). The absorbance of each sample 
was measured at 560 nm using a microplate reader (GENios, Tecan). The percentage cell 
viability was calculated relative to the control treated cultures. 
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2.10  Subcutaneous mouse model of colon cancer 
Bioware ULTRA cell lines HCT 116- luc2 were purchased from Caliper LS (MA, USA).  
These cells were treated ex vivo with either control siRNA or siRNA targeting Rpt4.  After 48 
h, 2.5 x 106 cells were implanted with subcutaneous injection into the right flank of Balb-c 
nu/nu mice (Charles River, USA).  Ethical approval was granted by our local and institutional 
ethical committee. The mice were imaged 24 h post implantation to ensure cell viability using 
an IVIS Spectrum scanner (Caliper LS).  Imaging occurred 10 min post intraperitoneal 
administration of 150 mg/kg body weight D-luciferin (Caliper LS).  Weekly bioluminescent 
imaging occurred thereafter, until endpoint (tumour size) 15 mm. Tumour size was measured 
and mouse weights were recorded every 72 h.  Tumour volume was then calculated using a 
previously published modified ellipsoidal formula (Euhus et al., 1986).  After killing, the 
tumour and internal viscera were analysed and imaged ex vivo.   
 
2.11  Formulation and characterisation of CPP:siRNA nanoparticles 
The cell penetrating peptide, Octa-arginine (CPP) (Genscript, NJ, USA) was dissolved in 
RNA-ase free water to achieve required concentrations.  siRNA of either the control sequence 
or Rpt4 was added dropwise to CPP solution, at ratios of  9:1, 25:1 and 50 : 1 CPP : siRNA.  
After addition of the siRNA, the solution was stirred on magnetic stirrer for 6 h at room 
temperature to form nanoparticles. The average particle size, polydispersity index (PDI) and 
zeta potential (ZP) of the nanoparticles was measured using a Zetasizer (Nanoseries, Nano-
ZS, Malvern Instruments,UK). The data is presented as the average of 5 measurements +/- 
standard deviation.  Efficacy of siRNA; CPP nanocomplexes were assessed by transfection of 
HCT-116 WT luc-2 ULTRA cells seeded on a 96 well plate, drawing comparison with 
transfection of siRNA using metafectene and using CPP only as a negative control.  MTT 
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assay enabled analysis of cytotoxicity in response to Rpt4 siRNA:CPP complexes.  4 
solutions for intratumoural delivery were prepared, at a ratio of 50:1 CPP:siRNA.  siRNA 
duplex (Sigma) concentrations were added dropwise to these solutions at concentrations of 1 
mg/kg Rpt4 siRNA, 0.3 mg/kg Rpt4 siRNA, 0.1 mg/kg siRNA integrated into R8 
nanocomplexes, and CPP alone as a control. 
 
2.12  In vivo delivery of siRNA nanocomplexes 
CPP:siRNA nanoparticles were delivered in vivo to mice with established subcutaneous 
tumours at least 3 x 3 mm in size.  Using nanoparticles prepared on the day of use, 6 
intratumoural injections were delivered to each mouse at an interval of 72 h apart with serial 
measurement of tumour size using calipers. Prior to injection, the mouse was anaesthetised 
with general inhalational anaesthetic and the overlying skin was sterilized.  A volume not 
exceeding 50 μl of CPP:siRNA solution or CPP alone was injected.  Puncture sites were 
alternated to minimize trauma induced local inflammatory reactions and ulceration. 
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3.0  Results 
 
3.1  Rpt4 protein levels increase in rectal tumours not responding to chemoradiation 
therapy 
Locally-advanced rectal cancer patients frequently receive neoadjuvant chemoradiation 
therapy prior to surgery in an attempt to downstage the tumour so it can be more completely 
removed at surgery. Approximately 40% of patients show no response to this treatment and 
display no tumour regression (Janjan et al., 2001; Lu et al., 2013).  To explore the role of 
Rpt4 in response to neoadjuvant chemoradiation, we obtained quality-assured rectal cancer 
biopsies prior to chemoradiation therapy. Western blot and subsequent densitometry analysis 
of pre-treatment tumour biopsy and matched normal tissue from 24 rectal cancer patients 
suggested that Rpt4 protein levels did not correlate with clinical responses as assessed by 
RCPath staging in both normal and tumour tissue (Fig. 1A).    
 
For those patients who did not respond to neoadjuvant chemoradiation therapy we also 
obtained post treatment surgical resection tissue, obtained following neoadjuvant 
chemoradiation therapy (n=6). This allowed us to compare Rpt4 protein expression pre- and 
post-treatment to assess any acute changes in protein expression in response to treatment in 
poor responding patients (Fig. 1B). Of note, neoadjuvant chemoradiation therapy 
significantly increased protein expression levels of Rpt4 in poor responding patients (Fig. 
1B,C, P = 0.039), suggesting that an increase in Rpt4 protein levels may be associated with 
resistance to chemoradiation therapy.  Increased Rpt4 protein expression was not seen in 
normal tissue (Fig. 1D), suggesting that this increase was limited to tumour tissue.  
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To investigate the association of Rpt4 protein levels with long term patient outcome we also 
examined Rpt4 protein levels in the resected primary tumour of a subset of 26 stage 2 and 3 
CRC patients. Kaplan Meier survival analysis of tumour tissue revealed that patients with 
Rpt4 levels below mean levels exhibited a statistically significant increase in survival time 
when compared to patients with above mean levels of Rpt4 protein (Fig. 1E, P = 0.032).  This 
correlation between increased survival and above mean levels of Rpt4 protein was not seen in 
patient matched normal mucosa (Fig. 1F).  This indicates that increased Rpt4 protein levels of 
normal tissue is not a prognostic marker for Stage 2 and 3 CRC patients in the setting of 
adjuvant treatment. 
 
3.2  Increased expression of Rpt4 in colon cancer cell lines 
We next investigated whether colon cancer cell lines exhibited detectable levels of Rpt4 
protein. In a panel of colon cancer cells with differing K-ras and TP53 status (HCT 116 wt 
and p53-/-; Colo 205, DLD-1, HT-29, and LoVo) the expression levels of Rpt4 were 
analysed by Western blotting and densitometric analysis (Fig. 2A). In addition, we included 
samples derived from a non-transformed colon epithelial cell line, CRL 1807 (ATCC).  As 
demonstrated in Fig. 2A,B, all of the colon cancer cell lines displayed similar levels of Rpt4 
expression. The non-transformed CRL 1807 had lower levels of Rpt4 protein when compared 
to the tumour cell lines. However, analysis of 20S core expression in these colon cancer cell 
lines and CRL 1807 did not mirror this increased proteasome subunit expression in the cancer 
cell lines (Fig. 2C,D) 
 
3.3  Small interfering RNA (siRNA) mediated knockdown of Rpt4 reduces proteasomal 
activity  
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To explore whether Rpt4 inhibition is a feasible approach for the treatment of colon cancer, 
we next sought to investigate the effects of inhibition of Rpt4 expression. We could 
demonstrate efficient knockdown of Rpt4 expression using two different siRNA sequences, 
with sequence 2 showing a more pronounced inhibition of Rpt4 expression (Fig. 3A).  Rpt4 
siRNA sequence 2 was therefore depicted for all of the subsequent experiments. We next 
investigated the potential of Rpt4 gene silencing on the function of the catalytic activity of the 
proteasome. We assayed for the three different enzymatic activities associated with the 26S 
proteasome.  Chymotrypsin-like activity of the proteasome is thought to be most 
representative of whole proteasomal function (Kisselev et al., 2006; Kisselev and Goldberg, 
2005). As demonstrated in Fig. 3B gene silencing of Rpt4 significantly reduced 
chymotrypsin-like proteasomal activity, but inhibition of trypsin-like activity was not 
statistically significant.  This was mirrored by the less marked reduction in trypsin-like 
activity after treatment with bortezomib (Fig. 3C). In contrast, the 26S subunit proteasome 
inhibitor bortezomib reduced both chymotrypsin- and trypsin-like protease activity. Caspase-
like activity was also affected by Rpt4 silencing (Fig. 3D).  
 
3.4  Gene silencing of Rpt4 induces endoplasmic reticulum (ER) stress  
As a component of the 19S proteasome, Rpt4 is not directly involved in the proteolytic 
activity associated with the proteasome, but  in the unfolding of the proteasome substrates 
and their movement into the 20S catalytic core of the proteasome for degradation. We 
therefore also explored whether Rpt4 gene silencing induced markers of the unfolded protein 
response by inhibiting the degradation of unfolded proteins targeted for the proteasome. 
Indeed, transfection of HCT-116 cells with Rpt4 siRNA induced a signficant upregulation of 
grp78 mRNA, a marker of endoplasmic reticulum stress and a target gene of the unfolded 
protein response (Fig.  4A).  This was also confirmed on the protein level, with increased  
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grp78 protein and increased accumulation of poly-ubiquitinated proteins evident in HCT116 
cells after Rpt4 gene silencing (Fig. 4B,C). 
 
3.5  Rpt4 deficiency induces apoptosis and reduces clonogenic survival in HCT-116 
colon cancer cells   
Next we investigated the functional consequences of decreased Rpt4 expression on the 
survival and growth of colon cancer cells in vitro. In order to quantitatively analyse the 
effects of Rpt4 knockdown on cell survival and proliferation we performed flow cytometry 
analysis to measure phosphatidylserine exposure using Annexin V staining as a marker of 
apoptotic cell death.  One of the major transcription factors whose expression is regulated by 
ubiquitylation and subsequent degradation by the proteasome is p53 which is frequently 
mutated in cancer cells. Previous studies have demonstrated that proteasomal inhibition 
induced cell death is at least in part p53 dependent (Concannon et al., 2006).  Therefore, we 
also included p53-deficient HCT-116 cells in these studies. Treatment of HCT-116 colon 
cancer cells or p53-deficient HCT-116 colon cancer cells with Rpt4 siRNA resulted in a 
significant time dependent increase in the number of cells staining positive for Annexin V, 
suggesting that Rpt4 reduction was sufficient to increase the levels of spontaneous cell death. 
The effect on cell survival was more pronounced in wild-type HCT-116 cells, with approx. 
40% of cells undergoing apoptosis after 72h (Fig. 5A).  When the non-transformed colon 
epithelial cell line, CRL 1807, was treated with Rpt4 siRNA, there was no increase in cell 
death levels when compared to control-transfected CRL 1807 cells (Fig. 5B) despite Rpt4 
reduction in these cells (Fig. 5C). 
 
To further assess the effects of Rpt4 inhibition, clonogenic survival assays were performed to 
examine survival and proliferation of HCT-116 cells following inhibition of Rpt4 expression. 
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HCT-116 cells were transfected with either control siRNA or siRNA sequences targeting 
Rpt4.  Following siRNA mediated knockdown for 72 h, the cells were counted and 1000 cells 
plated onto a 6 cm culture dish where they were allowed to expand for 10 days (Fig. 5D). The 
number of colonies formed in cells transfected with Rpt4 siRNA was significantly reduced 
compared to cells transfected with the control siRNA sequence.  Of note, silencing of Rpt4 
also induced strong effects in HCT-116 p53--/- cells that were comparable to those seen in 
HCT-116 cells.  Again, when the non-transformed colon epithelial cell line, CRL 1807, was 
treated with Rpt4 siRNA, there was no significant reduction in clonogenic survival when 
compared with control-transfected CRL 1807 cells (Fig. 5E). 
 
3.6  In vivo Rpt4 gene silencing using nanocomplexes as a potential strategy for the 
treatment of CRC  
Cellular delivery of siRNA is challenging due to its polyanionic nature, its rapid degradation 
and short in vivo half-life.  We finally investigated a strategy for the delivery of Rpt4 siRNA 
in vivo, using nanoparticles formed by electrostatic complexation of a cell-penetrating 
peptide, Octa-arginine (CPP).   Characterization of these nanocomplexes demonstrated that 
particle size of 237.9 nm was achieved with increasing ratios of CPP. The charge of the 
siRNA was also neutralized and a net overall positive charge was achieved with increasing 
CPP ratio (Table 1). In order to evaluate the optimal means to achieve Rpt4 gene silencing in 
vitro and in vivo, CPP nanocomplexes generated with a variety of CPP:siRNA ratios were 
added to HCT-116 cells cultured in vitro. Cell death in response to transfection of siRNA 
using these nanocomplexes was compared to our established protocol for transfection of 
siRNA using Metafectene as a positive control. Cell death in response to Rpt4 gene inhibition 
using these CPP:siRNA nano-complexes at a ratio of 50:1 was sustained at 12 h and 48 h post 
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transfection at a level exceeding that of metafectene based transfection protocols (Fig. 6 A, 
B). 
 
Next, using a HCT-116 luc2 ULTRA colon cancer tumour mouse model, nanoparticles were 
delivered via local intratumoural injection, increasing the likelihood of intracellular release of 
the siRNA payload and hence achieving the therapeutic goal of Rpt4 gene silencing. We 
found that mice with subcutaneous colon cancer cell line derived tumours had smaller tumour 
burden, with consequent enhanced survival benefit at all doses of nucleic acid targeting Rpt4 
(Fig. 6C, D).  Interestingly, at doses of 0.1 mg/kg siRNA delivered over 9 doses, optimal 
survival advantage was achieved (average survival 45.7 days) compared with tumour cells 
transfected with control siRNA (average survival 33.5 days) in a statistically significant 
manner (Log Rank Mantel Cox Test) (Fig. 6E, F).  
 
 
4.0  Discussion  
Due to the significance of the ubiquitin-proteasome pathway (UPP) in cell signalling, 
proteasome inhibitors have emerged as a new group of chemotherapeutic agents for the 
treatment of malignancies. Although the effects of proteasome inhibition on the activation of 
signaling pathways and downstream processes may vary in different cancers (Bajorek et al., 
2003), these agents have demonstrable therapeutic benefits in both haematological (Arnold 
and Grune, 2002) and solid malignancies (Crawford et al., 2011; Johnson, 2015; Kisselev and 
Goldberg, 2001), either as sole therapeutic agents or in combination with cytotoxic therapies 
(Bazzaro et al., 2006; Cusack, 2003; Russo, 2001). Proteasome inhibitors have been shown to 
inhibit cell-cycle progression and to induce apoptosis and cell death in a wide range of cancer 
cells in vivo and in vitro (Crawford et al., 2011; Ling et al., 2003). They act through a variety 
of mechanisms, including p53 stabilization, alterations in gene expression, and inhibition of 
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caspase degradation, among many others (Eldridge and O'Brien, 2009). Proteasome inhibitors 
have also been shown to overcome chemotherapy and radiotherapy resistance through 
inhibition of IκB degradation (Chen et al., 2011; Reddy and Czuczman, 2010; Russo, 2001). 
However, targeting the ubiquitin-proteasome system using a non-specific proteasome 
inhibitor such as bortezomib in malignancy is limited by the wide range of side effects to 
which patients may be subjected given that over 80% of intracellular proteolysis is controlled 
and effected by the proteasome (Wang and Maldonado, 2006).  As a result, proteasome 
inhibitors have a narrow therapeutic index.  Bortezomib targets the 20S proteasome catalytic 
core, attenuating cell proliferation and survival, and has proven effect in metastatic colorectal 
cancer (Kozuch et al., 2008).  Other mechanisms seen in cancer cells treated with this drug 
include reports of upregulation of pro-survival proteins in response to proteasome inhibition 
(Milano et al., 2009), and stability of p53 expression in treated cells and tissues, although 
pro-apoptotic effects are also demonstrated in cells which do not express p53 (Lenz; Ling et 
al., 2003).  In addition, the property of differential susceptibility of cancer cells to bortezomib 
and other proteasome inhibitors is part mediated by NF-kappaB pathways (Hideshima et al., 
2009).  Alternative therapeutic approaches may target components of the 19S proteasomal 
subunit, modulating proteasome assembly and the efficacy of individual proteasome subunits.  
Diversification of therapeutic agents within the Ubiquitin-Proteasome Pathway spectrum may 
offer alternatives to bortezomib with improved side-effect profiles and still harness the 
potential for synergistic enhancement of chemotherapy effect when used in tandem with 
proteasome inhibition.    These factors have encouraged efforts to seek novel and more 
specific therapeutic targets for cancer therapy within the ubiquitin-proteasome system.  We 
here tested the hypothesis that Rpt4, as a 19S proteasome subunit may be a valid target for 
the treatment of CRC.   
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We focused on the role of Rpt4 in colon cancer cell survival, as Rpt4 is a component of the 
19S proteasome and not directly involved in the proteolytic activity associated with the 
proteasome. Rather, Rpt4 is involved in the unfolding of the proteasome substrates and their 
movement into the catalytic core of the proteasome for degradation. We have demonstrated 
that Rpt4 inhibition inhibited cell proliferation, reduced clonogenic survival, and induced 
apoptosis in colon cancer cells, and that this was associated with an increased ER stress 
response.  p53 wt cells had higher levels of apoptosis on flow cytometry than p53 -/- cells.  
However there was no significant difference in attenuation of clonogenic survival after Rpt4 
reduction in p53 -/- and p53 wt cells. p53 induction has previously been shown after use of 
proteasome inhibitors in cancer cells (Lopes et al., 1997), and proteasome inhibitor-induced  
apoptosis has been shown to be largely p53-dependent (Concannon et al., 2006).  In contrast, 
clonogenic survival assays are a read-out of multiple cellular processes where apoptosis is not 
the sole determinant (Lo Nigro et al., 2007; Russell and Ling; Russell et al., 1995).  Our data 
suggest that there are multiple, p53-independent anti-proliferative mechanisms involved in 
the response to Rpt4 silencing, such as transcriptional machinery assembly (see below). 
 
Rpt4 is a member of the AAA class of ATPases, forming a heterohexameric ring with Rpt 1-
6, which attaches to the base of the 19S regulatory particle.  Finley and colleagues have 
shown in yeast studies that the C termini of Rpt4 and Rpt6 are crucial for assembly of this 
regulatory particle (Park et al., 2011; Park et al., 2009).  The effects of destabilisation of the 
regulatory particle and core particle interactions are demonstrated in our assays of reduced 
proteasome activity in response to Rpt4 gene silencing.  This reduction in activity may also 
relate to lower RP concentrations in the cell resulting in less 26S proteasome formation.  We 
have found that Rpt4 inhibits proteasome activity, with significant inhibition of 
chymotrypsin-like and caspase-like activity (Fig. 3).  Although there was a trend towards 
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inhibition of trypsin-like activity, this did not reach statistical significance.  However, our 
chosen proteasome activity assay may overestimate the effect of Rpt4 on this activity as Rpt4 
inhibition is likely to lead to lower cellular RP concentrations which would lend to CP 
presentation in a closed conformation and hence reduce potential fluorescent peptide 
cleavage.   
 
It should also be noted that while Rpt 1-6 have critical roles in the unfolding of 
polyubiquitinated substrates for translocation into the proteasome core and subsequent 
proteolysis, within the regulatory particle they do not have identical functions.  While their 
presence is required for the stoichometric stability of the proteasome complex, individual 
mutations affect proteasome activity and non-proteolytic functions in a variety of manners, 
outlining their functional heterogeneity (Bar-Nun and Glickman, 2012; Rubin et al., 1998).  
Tumours bear hallmarks of genomic instability which has been exploited to unveil potential 
novel therapeutic targets and mechanisms of pathogenesis.  The CYCLOPS genes identified a 
panel of genes which demonstrate partial loss in tumours, rendering them dependent of 
remaining alleles.  Many of these genes are involved in proteasome activity such as PSMC7 
(Rpt1).  Inhibition of the remaining allele expressing PSMC7 led to attenuated tumour growth 
and inhibition of cell proliferation (Nijhawan et al., 2012).  Furthermore, 26S proteasome 
levels may be limited by 19S complex levels as there was more expression of 20S, and we 
believe that inhibition of these 19S subunits including Rpt4 which has a strong assembly 
phenotype, induces proteasome stoichometric instability and reinforces the argument to target 
these subunits to inhibit tumour development and growth. 
 
Interestingly, proteasomal subunits can also perform functions independent of the proteolytic 
activity of the proteasome. 19S subunits have been reported to play a role in transcriptional 
22 
 
machinery assembly (Truax et al., 2010).  Indeed, recent evidence points to the ability of 19S 
subunits to regulate transcriptional events. In particular, analysis of proteasomal independent 
functions of ATPases including Rpt4 and Rpt6 in Saccaromyces cerevisiae has demonstrated 
that these have alternative roles in gene silencing and achieve this by linking chromatin 
modifications (Ezhkova and Tansey, 2004). In HCT-116 colon cancer cells, an AAA ATPase 
of the 19S subunit was identified as a TNF-receptor associated protein-1 (TRAP-1) 
interacting protein, with effects on ubiquitylation independent of proteasomal function 
(Amoroso et al., 2011). While there is an established link between histone ubiquitylation and 
transcription contributing to these non-proteolytic functions of Rpt4, these pathways and 
mechanisms have not been fully uncovered.  In addition, Rpt4 gene mutations in yeast are 
associated with a phenotype particularly vulnerable to ER stress and with participation in 
aspects of ERAD.  These characteristics are not mirrored by other ATPase mutations (Lipson 
et al., 2008).   Further investigations will be required to elucidate the factors involved in the 
beneficial effect of Rpt4 inhibition on tumour cell proliferation.  
 
The pronounced effects on cell death and attenuation of clonogenic survival noted in vitro as 
well as the increased expression of Rpt4 in non-responding rectal tumours as seen in Fig. 1, 
drove our hypothesis that Rpt4 gene silencing may reduce tumour progression in vivo.  
Ideally we would also like to compare expression of Rpt4 in rectal tissue of a non-diseased 
cohort. In our subcutaneous tumour model in Balb/c nu-nu immunodeficient mice using 
luciferase expressing HCT 116 cells, cells transfected with siRNA targeting Rpt4 in vivo 
generated smaller tumours and a statistically significant survival improvement over control 
groups.  Our in vivo methods were therefore proof of principle studies to address our 
hypothesis that Rpt4 may attenuate tumor growth in an animal model.  Further data in the 
area of adverse effects of this more specific proteasome target would allow further 
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comparison with non-specific proteasome inhibitors in terms of unwanted systemic 
symptoms and consequences. 
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Figure Legends  
 
Figure 1: Neoadjuvant chemoradiation therapy significantly increased protein levels of 
Rpt4 in poor responding patients.  Biopsy tissue samples of 24 rectal cancer patients were 
obtained at colonoscopy or rigid sigmoidoscopy. (A) Densitometric analysis of Rpt4 
expression levels relative to  β-actin in biopsy tissue, tumour (T) and matched normal (N), of 
patients with varying pathological responses to radiochemotherapy. (B) Representative 
Western blot images of expression levels of Rpt4 (44 kDa) in tumour (T) and matched 
normal tissue (N) from both biopsy and surgical resection tissue. Probing with β-actin (42 
kDa) was applied as a loading control.  (C) Densitometric analysis of Rpt4 expression levels 
relative to β-actin in biopsy tissue and matched surgical resection tissue indicates that 
neoadjuvant chemoradiation therapy significantly increased expression levels of Rpt4  (n=6; 
*P = 0.039, log-rank test).  (D)  Densitometric analysis of Rpt4 expression relative to β-actin 
tumour and matched normal tissue.  Rpt4 expression is not significantly increased in normal 
mucosa, suggesting that this is specific to tumour tissue (n = 6; P > 0.05, log-rank test)  (E) 
Kaplan Meier survival analysis of high and low levels of Rpt4 relative to β-actin in tumour 
tissue stage 2 and 3 colon cancer patients.  Survival was prolonged in the patient group that 
had below mean levels of Rpt4  [*P = 0.032, n = 26, log-rank (Mantel Cox) test].  (F) Kaplan 
Meier survival analysis of high and low levels of Rpt4 relative to β-actin in matched normal 
tissue of stage 2 and 3 colon cancer patients.  [P = 0.48, n = 26, log-rank (Mantel Cox) test]. 
 
Figure 2: Rpt4 and 20S proteasome subunit levels in colon cancer cell lines. (A) 
Representative cropped Western Blot analysis of Rpt4 (44 kDa) expression levels in a panel 
of colon cancer cell lines and the epithelial cell line CRL 1807. Probing with α-tubulin (50 
kDa) was applied as a loading control.  (B) Densitometric analysis of Rpt4 expression levels 
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in colon cancer cell lines expressed relative to the non transformed colon epithelial cell CRL 
1807. (C) Western Blot analysis of 20S core particle (BioMol) expression levels in colon 
cancer cell lines with α-tubulin applied as loading control.  (D): Densitometric analysis of 
20S core particle expression levels in colon cancer cells.  Expression of  Rpt4 and 20S was  
normalised to α tubulin and then compared to  CRL 1807.  Data are mean +/- S.E.M of n=3 
independent determinations.  
 
Figure 3: Rpt4 gene silencing modulates proteasomal activity in a HCT-116 colon cancer 
cells. (A) Western Blot of Rpt4 expression in HCT 116 WT cell lines following transfection 
with two different siRNA sequences targeting Rpt4 in comparison with a control siRNA 
sequence.  Samples were harvested 48 h after transfection. Probing with α-tubulin served as a 
loading control.  (B) Inhibition of Rpt4 expression was confirmed using qPCR (*P = 0.0025).   
Data represent mean +/- S.E.M. (*P < 0.05, unpaired t-test, n=3.) (C-E)  HCT 116 wt cells 
were treated for 72 h with either scrambled siRNA or a siRNA targeting Rpt4. Cells were 
lysed and agitated prior to analysis of proteasome activity.  Proteasome activity was analysed 
using analysis of fluorescence levels following addition of reaction buffer and substrate 
specific to (C) chymotrypsin-like, (D) trypsin-like or (E) caspase-like. A fourth group of 
untransfected cells was treated 4 hs prior to analysis with the proteasome inhibitor 
Bortezomib (Bort.; 50 nM) as indicated. Activity was assessed as described in the materials 
and methods.  Data are mean +/- S.E.M of n=4 independent samples per group in C, D and n 
= 3 in E.  *P < 0.05 compared to Control siRNA group (ANOVA post-hoc Tukey). 
 
Figure 4 : Rpt4 gene silencing induces proteasomal and ER stress.  A: Using qPCR 
analysis, we evaluated expression levels of markers of ER stress in HCT 116 WT colorectal 
cancer cells, 24 hs after treatment with siRNA targeting Rpt4 (Sigma).  Upregulation of 
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expression levels of Grp78 (*P = 0.0189) was observed, with expression over 2 fold higher in 
cells following treatment with siRNA targeting Rpt4.  This is in keeping with our analysis 
that ER stress as well as induction of the UPR in response to ERAD impairment occurs in 
this colorectal cancer cell line following Rpt4 knockdown. Inhibition of Rpt4 expression was 
confirmed using qPCR (*P = 0.0025).   Data represent mean +/- S.E.M. (*P < 0.05, ANOVA 
post-hoc Tukey, n = 3.)  B: 24 h following treatment of HCT 116 WT colon cancer cells with 
siRNA targeting control sequence or Rpt4, Western blot analysis was used to evaluate 
expression of polyubiquitylated proteins and Grp 78/KDEL, markers of proteasomal stress 
and ER stress respectively.  α-tubulin was used as a loading control.  C: The expression of 
polyubiquitylated proteins and Grp 78/KDEL was analysed by densitometry in Rpt4 
knockdown cells relative to control.  Data represent mean +/- S.E.M (n = 3 independent 
determinations).  
 
Figure 5: Inhibition of Rpt4 expression induces cell death and attenuates clonogenic 
survival of colon cancer cells. (A) HCT116 cells and (B) CRL 1807 cells were transfected 
for 72 h with siRNA targeting Rpt4 or control siRNA and cell death was measured by 
Annexin V staining and subsequent flow cytometry. *P < 0.05 compares to Control siRNA 
(ANOVA post-hoc Tukey). (C)  Western Blot analysis of Rpt4 expression levels CRL 1807 
with α-tubulin applied as loading control.  CRL 1807 non transformed colonic epithelial cells 
were transfected using siRNA targeting Rpt4 (Sigma) to achieve Rpt4 gene silencing, and 
Rpt4 expression was assessed after 48 h. (D) HCT116 wt, HCT116 p53-/- cells and (E) CRL 
1807 non transformed colon epithelial cells were transfected with either Control or Rpt4 
siRNA (Sigma) for 72 h and clonogenic survival assays performed. Colonies were counted 
and expressed relative to the control siRNA transfected cells of each genotype. Data are mean 
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+/ - S.E.M from n=3 independent determinations per time condition. *P < 0.05 compared to 
Control siRNA treated cells (ANOVA post-hoc Tukey).  
 
Figure 6: Nanocomplex-mediated delivery of small interfering RNA targeting the 19S 
proteasomal subunit, Rpt4, reduces tumour growth and increases survival in vivo. (A, 
B) Characterization of the effect of nanocomplexes on cell survival in vitro. In order to 
evaluate the optimal means to achieve Rpt4 gene silencing, CPP:siRNA complexes were used 
at a ratio of 50:1. Cell death of HCT116 cells in response to Rpt4 gene inhibition using the 
CPP:siRNA complexes was sustained at (A) 12 h and (B) 48 h post transfection at a level 
exceeding that of metafectene based transfection protocols.  Cell death was evaluated using 
an MTT assay. Data represent mean +/- S.E.M.  (*P < 0.05, unpaired student t-test, n = 6). 
(C) Tumour growth in vivo.  Photographic representation of tumour burden in mice implanted 
with HCT 116 WT-luc2 ULTRA colon cancer cells (Caliper LS) and treated in vivo using 
intratumoural injection of control scrambled sequence siRNA or siRNA targeting Rpt4 at 
doses of 0.1 mg/kg recorded serially before and during treatment.  (D) Tumour 
Bioluminescence in vivo.  Photographic depiction of tumour bioluminescence in p/sec/cm2 
recorded serially in mice representative of study groups shown. (E,F) Kaplan Meier survival 
analysis of tumour bearing mice treated in vivo using intra-tumoural injection of control 
scrambled sequence siRNA (n = 6) or siRNA targeting Rpt4 at doses of 0.1 mg/kg, 0.3 mg/kg 
and 1 mg/kg (n = 8 per group).  Control groups are identical in Figure 5 D and E, but graphs 
are shown separately for clarity. Survival was prolonged in all groups treated with siRNA 
targeting Rpt4 but was most marked in the group treated at a dose of 0.1 mg/kg.  Statistical 
significance was reached in the groups treated at doses of 0.1 mg/kg and 1.0 mg/kg.  Data 
represent mean +/- S.E.M. [*P < 0.05, log rank (Mantel Cox)]. 
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Table 1:  Particle size and zeta potential of CPP:siRNA nanoparticles 
 
 
 
 
 
 
 
 
 
The average particle size, polydispersity index (PDI) and zeta potential (ZP) of the 
nanoparticles was measured using a Zetasizer (Nanoseries, Nano-ZS, Malvern 
Instruments,UK).   Data is presented as the average of 5 measurements +/- standard 
deviation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R8:siRNA ratio Size (nm) PDI Zeta potential (mV) 
siRNA  478.63 ± 29.68 0.64 ± 0.20 -17.67 ± 4.53 
9:1 461.33 ± 10.21 0.41 ± 0.04 7.40 ± 1.25 
25:1 347.37 ± 19.74 0.37 ± 0.05 11.31 ± 2.71 
50:1 237.87 ± 11.97 0.42 ± 0.04 12.63 ± 0.51 
